Atay Oguzhan sold $1.5M of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 12,500 indirectly-held shares of BillionToOne, Inc. (BLLN) at an average of $122.05 ($118.81–$124.74, $1.53M total) across 14 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Jul 8, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

Traders may briefly reassess sentiment due to insider selling, but the pre-arranged nature reduces interpretive weight versus an unplanned sale.

02

Market read

A $1.53M open-market insider sale under 10b5-1 is disclosed, likely causing only marginal sentiment impact absent other catalysts.

03

What to watch

The article notes indirect holdings and multiple small trades; without context on total insider ownership changes over time, the signal is limited.

Relevance 5/10Novelty 4/10Timing: today’s SEC Form 4 disclosure, after-hours filing timestamp

Background

The filing is an SEC Form 4 insider transaction by the company’s Chairman and CEO, explicitly tied to a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CEO Atay Oguzhan sold $1.53M of BLLN shares via a Rule 10b5-1 plan, filing a Form 4 on July 8.

Expected impact

Likely minimal, though it can add short-term overhang if traders interpret it as supply or confidence signal.

Evidence & confidence

The filing specifies an open-market sale and confirms a pre-arranged 10b5-1 plan; the article provides no new operational, financial, or regulatory catalyst.

Market effects

No sector-level read-across; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

10b5-1 sales are often mechanical and may reflect diversification or liquidity needs rather than bearish expectations.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Atay Oguzhan

    Chairman and CEO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.